肝癌是一种全身性疾病，机体的其他器官可受到肝癌发生发展的影响，并可能影响肝癌的发生发展。血小板是机体凝血系统的重要成分，并且参与多种实体肿瘤的发生发展。血小板的生成、储存及破坏受到肝脏的调控，血小板功能异常与多种肝脏疾病如肝脏再生和慢性肝脏疾病的发生发展密切相关。肝癌患者常存在血小板数量及功能的异常，但血小板与肝癌发生发展的关系及与肝癌预后的关系尚不明确。本项目拟从肝癌患者的临床病理资料入手，首先明确血小板与肝癌临床病理资料及肝癌预后的关系；其次建立DEN诱导的小鼠肝癌模型和裸鼠皮下荷瘤模型，研究抑制血小板活化对肝癌发生发展的影响，同时检测相关信号分子的变化，探讨相关的分子机制；最后利用血小板与肝癌细胞系体外共培养体系，研究血小板影响肝癌发生发展的机制。本项目的研究结果将有助于深入理解肝癌的发生发展机制，寻找有效的肝癌防治靶点，对肝癌的治疗预防有重要意义。

Hepatocellular carcinoma (HCC)is a kind of systemic diseases. Besides the liver, other organs of the body can be affected by HCC, and the pathology of these organs may contribute to HCC development. Understanting the interaction between liver and other organs during hepatocarcinogenesis critical for the identification of novel therapeutic targets for liver disease. Platelets are anucleate cells that are crucial mediators of haemostasis. Increasing evidence show that platelets are involved in the pathophysiology of several diseases, including inflammation and cancer.The production and destruction of platelets are tightly regulated by the liver,and platelets are in close association with many liver diseases, such as liver regeneration and chronic liver diseases. Platelet abnormality is often found in HCC patients, however, the relationship between platelet and HCC development and prognosis is unclearly. In this study, we will analyze clinical data of HCC　patients to clarify the correlation between platelets and clinical features of HCC. Then by using xenograft tumor model and DEN-induce tumorigenesis model, we are to determine the effects of antiplatlet agents on the development of HCC. Finally, we will use the co-culture model to study the mechanism how platelets are involved in HCC development. Our results will shed new light on the pathogenesis of HCC and help to find new targets for HCC prevention and treatment. Our study will also provide important preclinical data for the use of antiplatelet regimen in HCC prevention.